These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39258756)

  • 1. Predicting CDR status over 36 months with a recall-based digital cognitive biomarker.
    Bruno D; Jauregi-Zinkunegi A; Bock JR;
    Alzheimers Dement; 2024 Oct; 20(10):7274-7280. PubMed ID: 39258756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Digital Cognitive Biomarkers for Alzheimer's Disease: Identifying Cognitive Process Changes and Impending Cognitive Decline.
    Bock JR; Hara J; Fortier D; Lee MD; Petersen RC; Shankle WR
    J Prev Alzheimers Dis; 2021; 8(2):123-126. PubMed ID: 33569557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.
    Polhamus DG; Dolton MJ; Rogers JA; Honigberg L; Jin JY; Quartino A
    J Prev Alzheimers Dis; 2023; 10(2):212-222. PubMed ID: 36946448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normative Data of Mini-Mental State Examination, Montreal Cognitive Assessment, and Alzheimer's Disease Assessment Scale-Cognitive Subscale of Community-Dwelling Older Adults in Taiwan.
    Wei YC; Chen CK; Lin C; Chen PY; Hsu PC; Lin CP; Shyu YC; Huang WY
    Dement Geriatr Cogn Disord; 2022; 51(4):365-376. PubMed ID: 35820405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting conversion of patients with Mild Cognitive Impairment to Alzheimer's disease using bedside cognitive assessments.
    Clarke A; Ashe C; Jenkinson J; Rowe O; A D N I ; Hyland P; Commins S
    J Clin Exp Neuropsychol; 2022 Dec; 44(10):703-712. PubMed ID: 36803664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
    Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
    Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Clinical Dementia Rating Using Blood RNA Levels.
    Miller JB; Kauwe JSK
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32604772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal clinically important difference in Alzheimer's disease: Rapid review.
    Muir RT; Hill MD; Black SE; Smith EE
    Alzheimers Dement; 2024 May; 20(5):3352-3363. PubMed ID: 38561021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.
    Yagi T; Kanekiyo M; Ito J; Ihara R; Suzuki K; Iwata A; Iwatsubo T; Aoshima K; ;
    Alzheimers Dement (N Y); 2019; 5():364-373. PubMed ID: 31440579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond?
    Balsis S; Benge JF; Lowe DA; Geraci L; Doody RS
    Clin Neuropsychol; 2015; 29(7):1002-9. PubMed ID: 26617181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychometric Properties of Alzheimer's Disease Assessment Scale-Cognitive Subscale for Mild Cognitive Impairment and Mild Alzheimer's Disease Patients in an Asian Context.
    Zainal NH; Silva E; Lim LL; Kandiah N
    Ann Acad Med Singap; 2016 Jul; 45(7):273-83. PubMed ID: 27523508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remote neuropsychological assessment of elderly Japanese population using the Alzheimer's Disease Assessment Scale: A validation study.
    Yoshida K; Yamaoka Y; Eguchi Y; Sato D; Iiboshi K; Kishimoto M; Mimura M; Kishimoto T
    J Telemed Telecare; 2020; 26(7-8):482-487. PubMed ID: 31068063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation study of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease.
    Nogueira J; Freitas S; Duro D; Almeida J; Santana I
    Clin Neuropsychol; 2018; 32(sup1):46-59. PubMed ID: 29566598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation study of the Alzheimer's Disease Assessment Scale-Cognitive Subscale for people with mild cognitive impairment and Alzheimer's disease in Chinese communities.
    Yang H; Cheng Z; Li Z; Jiang Y; Zhao J; Wu Y; Gu S; Xu H
    Int J Geriatr Psychiatry; 2019 Nov; 34(11):1658-1666. PubMed ID: 31347192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrepancy-Based Evidence for Loss of Thinking Abilities (DELTA): Development and Validation of a Novel Approach to Identifying Cognitive Changes.
    Asken BM; Thomas KR; Lee A; Davis JD; Malloy PF; Salloway SP; Correia S
    J Int Neuropsychol Soc; 2020 May; 26(5):464-479. PubMed ID: 31822312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data.
    Ben Jemaa S; Attia Romdhane N; Bahri-Mrabet A; Jendli A; Le Gall D; Bellaj T
    J Alzheimers Dis; 2017; 60(1):11-21. PubMed ID: 28505978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.